// App-Quantinova.ai

4504 : Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC) Results from Cohorts 3, 4, 5 of the COSMIC-021 study.

Researchers

Presenter

  • Sumanta K. Pal

Principal Investigators

  • Neeraj Agarwal

  • Parminder Singh

  • Andrea Necchi

  • Bradley Alexander McGregor

  • Ralph J. Hauke

  • Thomas Powles

  • Cristina Suárez

  • Carla M.L.- Van Herpen

  • Ulka N. Vaishampayan

  • Ramu Sudhagoni

  • Dominic Curran

  • Lana Andrianova

  • Yohann Loriot

Medical Centers

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Department of Surgery, Mayo Clinic, Phoenix, AZ

  • Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy

  • Dana-Farber Cancer Institute, Boston, MA

  • Nebraska Cancer Specialists - Midwest Cancer Center, Omaha, NE

  • Barts Health NHS Trust St Bartholomew's Hospital, London, United Kingdom

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

  • University of Michigan, Ann Arbor, MI

  • Exelixis, Alameda, CA

  • Centre Hospitalier Universitaire, Institut Gustave Roussy, Villejuif, France

Locations

  • United States

  • Italy

  • United Kingdom

  • Spain

  • Netherlands

  • France

Companies

  • Exelixis, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Atezolizumab

  • Cabozantinib

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03170960

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved